JP2008530011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530011A5 JP2008530011A5 JP2007554205A JP2007554205A JP2008530011A5 JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5 JP 2007554205 A JP2007554205 A JP 2007554205A JP 2007554205 A JP2007554205 A JP 2007554205A JP 2008530011 A5 JP2008530011 A5 JP 2008530011A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pyridin
- pyrazol
- alkyl
- oxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 77
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 63
- 125000000623 heterocyclic group Chemical group 0.000 claims 49
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000003118 aryl group Chemical group 0.000 claims 32
- -1 carbocycle Chemical group 0.000 claims 30
- 125000004452 carbocyclyl group Chemical group 0.000 claims 27
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 16
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 13
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 125000004429 atom Chemical group 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000003951 lactams Chemical class 0.000 claims 7
- 150000002596 lactones Chemical class 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 125000006239 protecting group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- JQGPBDSMTHZOMO-UHFFFAOYSA-N OBO.C=1C=NNC=1 Chemical class OBO.C=1C=NNC=1 JQGPBDSMTHZOMO-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 235000010290 biphenyl Nutrition 0.000 claims 2
- 239000004305 biphenyl Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- IZQZVLNYVZCOPX-UHFFFAOYSA-N 2-[2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethylamino]ethanol Chemical compound N=1N(CCNCCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 IZQZVLNYVZCOPX-UHFFFAOYSA-N 0.000 claims 1
- FKWQBUGNQFJRGV-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound N=1N(CCO)C=C(C=2C=C3OCOC3=CC=2)C=1C1=CC=NC=C1 FKWQBUGNQFJRGV-UHFFFAOYSA-N 0.000 claims 1
- MJESHTQDIHRJJJ-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 MJESHTQDIHRJJJ-UHFFFAOYSA-N 0.000 claims 1
- IEPBUTPKELRFKK-UHFFFAOYSA-N 2-[4-(1-amino-2,3-dihydro-1h-inden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound C=1C=C2C(N)CCC2=CC=1C=1C=NN(CCO)C=1C1=CC=NC=C1 IEPBUTPKELRFKK-UHFFFAOYSA-N 0.000 claims 1
- PKGNJPQGDHTVGY-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridine-3-carbonitrile Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C=2C(=CC=CN=2)C#N)N=C1C1=CC=NC=C1 PKGNJPQGDHTVGY-UHFFFAOYSA-N 0.000 claims 1
- SQFQKKPNPXONBG-UHFFFAOYSA-N 2-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-5-pyridin-4-ylpyrazol-1-yl]ethanol Chemical compound OCCN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 SQFQKKPNPXONBG-UHFFFAOYSA-N 0.000 claims 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 claims 1
- VATRAMGKPXJFAV-UHFFFAOYSA-N 3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propane-1,2-diol Chemical compound N=1N(CC(O)CO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 VATRAMGKPXJFAV-UHFFFAOYSA-N 0.000 claims 1
- RCBZCSONTXNSHW-UHFFFAOYSA-N 4-[1-piperidin-4-yl-4-[6-(1h-pyrazol-5-yl)-2,4,5,6-tetrahydro-1h-inden-5-yl]pyrazol-3-yl]pyridine Chemical compound C1C2=CCCC2=CC(C2=NNC=C2)C1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 RCBZCSONTXNSHW-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- RICPRHNLFHUQIT-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1,3-dihydroindol-2-one Chemical compound N=1N(C)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 RICPRHNLFHUQIT-UHFFFAOYSA-N 0.000 claims 1
- NWAIAPGJHCMCJQ-UHFFFAOYSA-N 5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound N=1N(C)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 NWAIAPGJHCMCJQ-UHFFFAOYSA-N 0.000 claims 1
- XIWGEASMKDCYFJ-UHFFFAOYSA-N 5-(5-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydroinden-1-one Chemical compound C=1C=C2C(=O)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 XIWGEASMKDCYFJ-UHFFFAOYSA-N 0.000 claims 1
- CACKWIAQZGWUDK-UHFFFAOYSA-N 5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3h-isoindol-1-amine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(=N)C3=CC=2)=C1 CACKWIAQZGWUDK-UHFFFAOYSA-N 0.000 claims 1
- DEZZLWQELQORIU-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 DEZZLWQELQORIU-UHFFFAOYSA-N 0.000 claims 1
- MGGQMXLSPADSGN-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1,3-dihydroindol-2-one Chemical compound N=1N(CCO)C=C(C=2C=C3CC(=O)NC3=CC=2)C=1C1=CC=NC=C1 MGGQMXLSPADSGN-UHFFFAOYSA-N 0.000 claims 1
- UMUDEJRSKACPSS-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-1h-quinazolin-4-one Chemical compound N=1N(CCO)C=C(C=2C=3C(=O)NC=NC=3C=CC=2)C=1C1=CC=NC=C1 UMUDEJRSKACPSS-UHFFFAOYSA-N 0.000 claims 1
- XRDGWIKOQYEFOL-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-one Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(=O)C3=CC=2)C=1C1=CC=NC=C1 XRDGWIKOQYEFOL-UHFFFAOYSA-N 0.000 claims 1
- UIBKJNFSKLXWTK-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydrophthalazine-1,4-dione Chemical compound N=1N(CCO)C=C(C=2C3=C(C(NNC3=O)=O)C=CC=2)C=1C1=CC=NC=C1 UIBKJNFSKLXWTK-UHFFFAOYSA-N 0.000 claims 1
- VFWDUSGVXPKDHF-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2-(2-methoxyethyl)isoindole-1,3-dione Chemical compound C1=C2C(=O)N(CCOC)C(=O)C2=CC=C1C1=CN(CCO)N=C1C1=CC=NC=C1 VFWDUSGVXPKDHF-UHFFFAOYSA-N 0.000 claims 1
- YNEHWTFXTODKTQ-UHFFFAOYSA-N 5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2h-isoquinolin-1-one Chemical compound N=1N(CCO)C=C(C=2C3=CC=NC(O)=C3C=CC=2)C=1C1=CC=NC=C1 YNEHWTFXTODKTQ-UHFFFAOYSA-N 0.000 claims 1
- SZOSXNZCMNUXFR-UHFFFAOYSA-N 5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-amine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(N)C3=CC=2)=C1 SZOSXNZCMNUXFR-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- HXGBUKKPDSRQTR-UHFFFAOYSA-N 6-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)naphthalen-1-ol Chemical compound N=1N(C)C=C(C=2C=C3C=CC=C(O)C3=CC=2)C=1C1=CC=NC=C1 HXGBUKKPDSRQTR-UHFFFAOYSA-N 0.000 claims 1
- RILYHIWSBNWFIQ-GMAHTHKFSA-N 6-[1-[(1s,2s)-2-hydroxycyclohexyl]-3-pyridin-4-ylpyrazol-4-yl]naphthalen-1-ol Chemical compound O[C@H]1CCCC[C@@H]1N1N=C(C=2C=CN=CC=2)C(C=2C=C3C=CC=C(O)C3=CC=2)=C1 RILYHIWSBNWFIQ-GMAHTHKFSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000019838 Blood disease Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- RMTGMEXYMKRUSY-UHFFFAOYSA-N N-[5-(1-methyl-5-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound CN1N=CC(C=2C=C3CCC(C3=CC=2)=NO)=C1C1=CC=NC=C1 RMTGMEXYMKRUSY-UHFFFAOYSA-N 0.000 claims 1
- HNYYFWGWLSEHQF-UHFFFAOYSA-N N-[5-(5-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CNN=C1C1=CC=NC=C1 HNYYFWGWLSEHQF-UHFFFAOYSA-N 0.000 claims 1
- BFXCZPXEDHBYBJ-UHFFFAOYSA-N N-[5-[1-(1-methylpiperidin-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-3H-isoindol-1-yl]hydroxylamine Chemical compound C1CN(C)CCC1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CNC(/C3=CC=2)=N\O)=C1 BFXCZPXEDHBYBJ-UHFFFAOYSA-N 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 201000000220 brain stem cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- RXOAUTDNEHGRQR-UHFFFAOYSA-N chembl524643 Chemical compound N=1N(C)C=C(C=2C=C3CNC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 RXOAUTDNEHGRQR-UHFFFAOYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 208000018706 hematopoietic system disease Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000033065 inborn errors of immunity Diseases 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000011061 large intestine cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- GBESZLUYUDEPLT-UHFFFAOYSA-N n-[3-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]propyl]-2-methoxyacetamide Chemical compound N=1N(CCCNC(=O)COC)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 GBESZLUYUDEPLT-UHFFFAOYSA-N 0.000 claims 1
- UMEKRJBKRPLHKL-UHFFFAOYSA-N n-[5-(1-cyclopentyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCCC2)N=C1C1=CC=NC=C1 UMEKRJBKRPLHKL-UHFFFAOYSA-N 0.000 claims 1
- ZDPNNLPNJKVPAJ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-1-benzofuran-3-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3C(=NO)COC3=CC=2)C=1C1=CC=NC=C1 ZDPNNLPNJKVPAJ-UHFFFAOYSA-N 0.000 claims 1
- PALWZOUPWYHIBZ-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydrochromen-4-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=3C(=NO)CCOC=3C=CC=2)C=1C1=CC=NC=C1 PALWZOUPWYHIBZ-UHFFFAOYSA-N 0.000 claims 1
- QULKREMAADOCHU-UHFFFAOYSA-N n-[5-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(C)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 QULKREMAADOCHU-UHFFFAOYSA-N 0.000 claims 1
- KWEFZSZCLBHIEQ-UHFFFAOYSA-N n-[5-(1-piperidin-4-yl-3-pyridin-4-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCNCC2)N=C1C1=CC=NC=C1 KWEFZSZCLBHIEQ-UHFFFAOYSA-N 0.000 claims 1
- BHLMLSGRHJUIKL-UHFFFAOYSA-N n-[5-(2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(=C1N=CC=CN1N=1)C=1C1=CC=NC=C1 BHLMLSGRHJUIKL-UHFFFAOYSA-N 0.000 claims 1
- DFDQKBZNHIAFHM-UHFFFAOYSA-N n-[5-(3-pyridin-4-yl-1-pyrrolidin-3-ylpyrazol-4-yl)-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CNCC2)N=C1C1=CC=NC=C1 DFDQKBZNHIAFHM-UHFFFAOYSA-N 0.000 claims 1
- OJMSXFJCMHLRGA-UHFFFAOYSA-N n-[5-[1-(2-aminoethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 OJMSXFJCMHLRGA-UHFFFAOYSA-N 0.000 claims 1
- DTGWIQVKISSKJV-UHFFFAOYSA-N n-[5-[1-(2-piperidin-1-ylethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C(C(=N1)C=2C=CN=CC=2)=CN1CCN1CCCCC1 DTGWIQVKISSKJV-UHFFFAOYSA-N 0.000 claims 1
- XBYGGIAFXHDSJP-UHFFFAOYSA-N n-[5-[1-(3-aminopropyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 XBYGGIAFXHDSJP-UHFFFAOYSA-N 0.000 claims 1
- RGMKIWCFVYETDM-UHFFFAOYSA-N n-[5-[1-(4-aminobutyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N=1N(CCCCN)C=C(C=2C=C3CCC(C3=CC=2)=NO)C=1C1=CC=NC=C1 RGMKIWCFVYETDM-UHFFFAOYSA-N 0.000 claims 1
- QPROAMYIMIWMOV-UHFFFAOYSA-N n-[5-[1-(4-methylpiperidin-1-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CC(C)CCN1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 QPROAMYIMIWMOV-UHFFFAOYSA-N 0.000 claims 1
- RZCDDUDKDKUXLC-UHFFFAOYSA-N n-[5-[1-(oxan-4-yl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN(C2CCOCC2)N=C1C1=CC=NC=C1 RZCDDUDKDKUXLC-UHFFFAOYSA-N 0.000 claims 1
- NOBRYXWIIOWOPC-QGZVFWFLSA-N n-[5-[1-[(3r)-oxolan-3-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C=1C=C2C(=NO)CCC2=CC=1C1=CN([C@H]2COCC2)N=C1C1=CC=NC=C1 NOBRYXWIIOWOPC-QGZVFWFLSA-N 0.000 claims 1
- AVUPTZCSKVHLFN-UHFFFAOYSA-N n-[5-[1-[2-(4-methylpiperazin-1-yl)ethyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1CN(C)CCN1CCN1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 AVUPTZCSKVHLFN-UHFFFAOYSA-N 0.000 claims 1
- BNZFFQFIDFWDFA-UHFFFAOYSA-N n-[5-[1-[3-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound NCC1=CC=CN=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 BNZFFQFIDFWDFA-UHFFFAOYSA-N 0.000 claims 1
- CYJGATFIVAHKTM-UHFFFAOYSA-N n-[5-[1-[4-(aminomethyl)phenyl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound C1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 CYJGATFIVAHKTM-UHFFFAOYSA-N 0.000 claims 1
- ZNRRHRJCCXLLCS-UHFFFAOYSA-N n-[5-[1-[5-(aminomethyl)pyridin-2-yl]-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydroinden-1-ylidene]hydroxylamine Chemical compound N1=CC(CN)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 ZNRRHRJCCXLLCS-UHFFFAOYSA-N 0.000 claims 1
- WWZAMNZDVNQWRK-UHFFFAOYSA-N n-[6-[4-(1-hydroxyimino-2,3-dihydroinden-5-yl)-3-pyridin-4-ylpyrazol-1-yl]pyridin-3-yl]acetamide Chemical compound N1=CC(NC(=O)C)=CC=C1N1N=C(C=2C=CN=CC=2)C(C=2C=C3CCC(C3=CC=2)=NO)=C1 WWZAMNZDVNQWRK-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- GEQCVKWGYURITF-UHFFFAOYSA-N tert-butyl n-[5-[1-(2-hydroxyethyl)-3-pyridin-4-ylpyrazol-4-yl]-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C=1C=C2C(NC(=O)OC(C)(C)C)CCC2=CC=1C1=CN(CCO)N=C1C1=CC=NC=C1 GEQCVKWGYURITF-UHFFFAOYSA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 125000005039 triarylmethyl group Chemical group 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* Chemical compound *C1C(*)=C(c2c(*)[n](*)nc2*)C(*)=C(CN2*)[C@]1C2=N* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005005P | 2005-02-04 | 2005-02-04 | |
| PCT/US2006/003654 WO2006084015A2 (en) | 2005-02-04 | 2006-02-02 | Raf inhibitor compounds and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008530011A JP2008530011A (ja) | 2008-08-07 |
| JP2008530011A5 true JP2008530011A5 (enExample) | 2009-02-26 |
Family
ID=36571626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554205A Pending JP2008530011A (ja) | 2005-02-04 | 2006-02-02 | Ｒａｆインヒビター化合物および方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7491829B2 (enExample) |
| EP (1) | EP1846391A2 (enExample) |
| JP (1) | JP2008530011A (enExample) |
| KR (1) | KR20070107104A (enExample) |
| CN (1) | CN101282960A (enExample) |
| AR (1) | AR053014A1 (enExample) |
| AU (1) | AU2006210626A1 (enExample) |
| BR (1) | BRPI0607346A2 (enExample) |
| CA (1) | CA2596973A1 (enExample) |
| CR (1) | CR9365A (enExample) |
| IL (1) | IL185024A0 (enExample) |
| MA (1) | MA29310B1 (enExample) |
| MX (1) | MX2007009405A (enExample) |
| NO (1) | NO20074473L (enExample) |
| RU (1) | RU2007133111A (enExample) |
| TW (1) | TW200639163A (enExample) |
| WO (1) | WO2006084015A2 (enExample) |
| ZA (1) | ZA200707289B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739595A (zh) | 2006-10-02 | 2014-04-23 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| MX2009004096A (es) | 2006-10-17 | 2009-06-16 | Stiefel Laboratories | Metabolitos de talarozol. |
| US20090082354A1 (en) * | 2007-09-20 | 2009-03-26 | Wyeth | Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
| WO2009111279A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
| KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| WO2009111260A1 (en) * | 2008-02-29 | 2009-09-11 | Wyeth | Phenylsulfonamide-substituted, pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| WO2009108827A1 (en) * | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| US20110003809A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CA2744563A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| JP2013503188A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Ｒａｆ阻害化合物およびその使用方法 |
| WO2011025938A2 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| US20120214811A1 (en) | 2009-08-28 | 2012-08-23 | Ignacio Aliagas | Raf inhibitor compounds and methods of use thereof |
| WO2011025947A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| US20120157451A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc | Raf inhibitor compounds and methods of use thereof |
| EP2470532A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
| JP5806672B2 (ja) * | 2009-10-30 | 2015-11-10 | ドメイン・セラピューティクス | 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用 |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
| EP2423210A1 (de) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Heteroarylpiperidin- und -piperazinderivate als Fungizide |
| US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
| WO2012055837A1 (de) | 2010-10-27 | 2012-05-03 | Bayer Cropscience Ag | Heteroarylpiperidin und -piperazinderivate als fungizide |
| EP2661434A4 (en) | 2011-01-06 | 2014-07-09 | Beta Pharma Canada Inc | NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| WO2012104273A1 (de) | 2011-02-01 | 2012-08-09 | Bayer Cropscience Ag | Heteroarylpiperidin und -piperazinderivate als fungizide |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| KR20140064971A (ko) | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2921481A1 (de) | 2011-12-27 | 2015-09-23 | Bayer Intellectual Property GmbH | 4-piperidine carboxylic acid derivatives |
| EP2797888B1 (en) * | 2011-12-31 | 2016-06-08 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| KR20240146112A (ko) | 2012-08-17 | 2024-10-07 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN104994879A (zh) | 2013-02-22 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 治疗癌症和预防药物抗性的方法 |
| JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| MX2015011899A (es) | 2013-03-15 | 2016-05-05 | Genentech Inc | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| ES2792183T3 (es) | 2013-09-13 | 2020-11-10 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| EP3122900A1 (en) | 2014-03-24 | 2017-02-01 | F. Hoffmann-La Roche AG | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック， インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| AR101210A1 (es) | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
| SG11201700496WA (en) | 2014-07-22 | 2017-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| JP7320741B2 (ja) | 2015-04-15 | 2023-08-04 | ベイジーン リミテッド | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 |
| CA2986441A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| JP6952691B2 (ja) | 2015-11-19 | 2021-10-20 | ジェネンテック， インコーポレイテッド | Ｂ−ｒａｆ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| MX2019007649A (es) * | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| CN110461847B (zh) | 2017-01-25 | 2022-06-07 | 百济神州有限公司 | (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途 |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2020005807A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP4021450B1 (en) | 2019-08-26 | 2025-11-05 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4211128A1 (en) | 2020-09-14 | 2023-07-19 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| BR112023007912A2 (pt) * | 2020-10-30 | 2024-01-02 | Novartis Ag | Formas cristalinas de um composto inibidor de kras g12c |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| KR20240090781A (ko) * | 2021-11-30 | 2024-06-21 | 아비스코 테라퓨틱스 컴퍼니 리미티드 | 피라졸 유도체, 그 제조방법 및 약학에서의 응용 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| TW202432544A (zh) | 2022-09-07 | 2024-08-16 | 美商亞文納營運公司 | 快速加速纖維肉瘤降解化合物及相關使用方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
| JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ［１，５−ａピリミジン誘導体 |
| PT714898E (pt) | 1994-06-21 | 2002-04-29 | Otsuka Pharma Co Ltd | Derivado de pirazolo¬1,5-a|pirimidina |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| CN1169149A (zh) | 1995-09-28 | 1997-12-31 | 株式会社大制药工场 | 止痛组合物 |
| JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
| JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
| JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
| EP1173254A2 (en) | 1999-04-27 | 2002-01-23 | Smithkline Beecham Plc | Novel treatment of neurotraumatic conditions with a raf inhibitor |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| CA2369076A1 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
| AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
| CZ20013540A3 (cs) | 2000-02-05 | 2002-03-13 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje |
| JP2003525936A (ja) | 2000-03-06 | 2003-09-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体 |
| CA2423154A1 (en) | 2000-09-21 | 2002-03-28 | David Kenneth Dean | Imidazole derivatives as raf kinase inhibitors |
| KR100843281B1 (ko) | 2000-12-28 | 2008-07-09 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환식 복소환 유도체 화합물 및 그 화합물을 유효성분으로 하는 의약 |
| ES2296910T3 (es) | 2001-01-22 | 2008-05-01 | Sankyo Company, Limited | Compuestos sustituidos con grupo amino biciclicos. |
| CA2440211A1 (en) * | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| ES2289116T3 (es) * | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
| CA2456187A1 (en) | 2001-08-03 | 2003-02-13 | Qing Tang | Pyrazole-derived kinase inhibitors and uses thereof |
| WO2003011855A2 (en) | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20040010027A1 (en) | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
| JP4286146B2 (ja) * | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピラゾール系調節剤 |
| JP4399265B2 (ja) * | 2001-12-21 | 2010-01-13 | ヴァーナリス（ケンブリッジ）リミテッド | ３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用 |
| ATE365740T1 (de) | 2002-05-10 | 2007-07-15 | Smithkline Beecham Corp | Substituierte pyrazolopyrimidine |
| GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| TW200417547A (en) | 2002-07-31 | 2004-09-16 | Smithkline Beecham Corp | Compounds |
| DE60309342T2 (de) * | 2002-08-09 | 2007-05-16 | Eli Lilly And Co., Indianapolis | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
| US6967254B2 (en) | 2002-09-09 | 2005-11-22 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1543001B1 (en) | 2002-09-17 | 2007-08-15 | Eli Lilly And Company | Pyrazolopyridine derivatives as tgf beta signal transduction inhibitors for the treatment of cancer |
| BR0314302A (pt) | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| AU2003290734A1 (en) * | 2002-11-27 | 2004-06-23 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/en not_active Ceased
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 CA CA002596973A patent/CA2596973A1/en not_active Abandoned
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 EP EP06734199A patent/EP1846391A2/en not_active Withdrawn
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Withdrawn
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008530011A5 (enExample) | ||
| RU2007133111A (ru) | Соединения, ингибирующие raf, и способы | |
| US20220251041A1 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
| US10369153B2 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| AU2001295026B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| JP4814783B2 (ja) | ピラゾロピリジン誘導体 | |
| JP6959248B2 (ja) | 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体 | |
| US7425557B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US7037918B2 (en) | Inhibitors of glycogen synthase kinase 3 | |
| US20060063789A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors | |
| US10047079B2 (en) | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | |
| US20130310395A1 (en) | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| AU2002363177A1 (en) | Aminobenzamide derivatives as glycogen synthase kinase 3Beta inhibitors | |
| JP2008540674A5 (enExample) | ||
| JP2024037913A (ja) | 化合物及びその使用 | |
| TW201609706A (zh) | 胺基嘧啶基化合物 | |
| US20140288044A1 (en) | Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors | |
| US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
| US20230069174A1 (en) | Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof | |
| KR20050033660A (ko) | Ｎ-바이아릴메틸 아미노사이클로알칸카복스아미드 유도체 | |
| JP6176244B2 (ja) | 芳香族複素環誘導体及び医薬 | |
| US20220218688A1 (en) | Pyridylpyridone compounds | |
| CA2999935A1 (en) | New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors | |
| EP3365337A1 (en) | Pyridone derivatives and their use as kinase inhibitors | |
| WO2025113806A1 (en) | Thiophene and thiazole derivatives as wip1 inhibitors |